

# Johnson & Johnson Innovative Medicine Pipeline

## Key Events in 2024\*

### POTENTIAL APPROVALS US/EU

- ✓ US **OPSUMIT (macitentan)**  
Pediatric Pulmonary Arterial Hypertension (TOMORROW)
- ✓ EU
- ✓ US **OPSYNVI (macitentan/tadalafil STCT)**  
Pulmonary Arterial Hypertension
- ✓ EU
- ✓ US **EDURANT (rilpivirine)**  
HIV pediatric 2-12 year old
- ✓ EU
- ✓ US\* **BALVERSA (erdafitinib)**  
Urothelial Cancer (THOR)
- ✓ EU
- ✓ US **DARZALEX (daratumumab)**  
Frontline multiple myeloma transplant eligible (PERSEUS)
- ✓ EU
- ✓ US **CARVYKTI (ciltacabtagene autoleucel)**  
Relapsed Refractory multiple myeloma w/1-3 PL (CARTITUDE-4)
- ✓ EU
- ✓ US **RYBREVANT (amivantamab)**  
Frontline Non Small Cell Lung Cancer in combination with chemotherapy (PAPILLON)
- ✓ EU
- ✓ US **RYBREVANT**  
Non Small Cell Lung Cancer 2L (MARIPOSA-2)
- ✓ EU
- ✓ US **RYBREVANT / LAZCLUZE**  
Non Small Cell Lung Cancer (MARIPOSA)
- ✓ EU
- ✓ US **TREMFYA (guselkumab)**  
Ulcerative Colitis (QUASAR)

### PLANNED SUBMISSIONS US/EU

- ✓ US **OPSUMIT (macitentan)**  
Pediatric Pulmonary Arterial Hypertension (TOMORROW)
- EU
- ✓ EU **UPTRAVI (selexipag)**  
Pediatric Pulmonary Arterial Hypertension (SALTO)
- ✓ EU
- ✓ EU **REKAMBYS**  
HIV Adolescents
- ✓ US **nipocalimab**  
Generalized Myasthenia Gravis
- ✓ EU
- ✓ US **SPRAVATO (esketamine) monotherapy**  
Treatment Resistant Depression (TRD4005)
- ✓ US **RYBREVANT (amivantamab)**  
Subcutaneous (PALOMA-3)
- ✓ EU
- ✓ US **DARZALEX (daratumumab)**  
Frontline multiple myeloma transplant eligible (PERSEUS)
- ✓ EU
- ✓ US **DARZALEX (daratumumab)**  
Frontline multiple myeloma transplant ineligible (CEPHEUS)
- ✓ EU
- US **DARZALEX (daratumumab)**  
Smoldering Multiple Myeloma (AQUILA)
- EU

- US **SIMPONI (golimumab)**  
EU Pediatric Ulcerative Colitis
- ✓ EU **STELARA (ustekinumab)**  
Pediatric Crohn's Disease
- US **TREMFYA (guselkumab)**  
Pediatric Psoriasis
- ✓ US **TREMFYA (guselkumab)**  
Crohn's Disease (GALAXI)
- ✓ EU
- US **TREMFYA (guselkumab)**  
Pediatric Juvenile Psoriatic Arthritis
- ✓ US **TREMFYA (guselkumab)**  
Ulcerative Colitis (QUASAR)
- ✓ EU
- US **TREMFYA (guselkumab)**  
Ulcerative Colitis Subcutaneous Induction (ASTRO)
- ✓ US **TREMFYA (guselkumab)**  
Crohn's Disease Subcutaneous Induction (GRAVITI)
- ✓ EU

### POTENTIAL CLINICAL DATA

#### Phase III

- ✓ **TREMFYA (guselkumab)**  
Crohn's Disease (GALAXI)
- ✓ **TREMFYA (guselkumab)**  
Ulcerative Colitis (QUASAR)
- ✓ **RYBREVANT (amivantamab)**  
Subcutaneous (PALOMA-3)
- ✓ **seltorexant**  
Adjunctive treatment for major depressive disorder with insomnia symptoms
- ✓ **nipocalimab**  
Generalized Myasthenia Gravis
- ✓ **TREMFYA (guselkumab)**  
Crohn's Disease Subcutaneous Induction (GRAVITI)
- ✓ **SPRAVATO (esketamine)**  
Treatment Resistant Depression monotherapy (TRD4005)
- DARZALEX (daratumumab)**  
Amyloidosis (ANDROMEDA)
- Phase II
- ✓ **nipocalimab**  
Sjogren's Disease (DAHLIAS)
- ✓ **TAR-200 (RIS/gemcitabine plus cetrelimab)**  
Non Muscle Invasive Bladder Cancer (SunRISe-1)